Since PIMA is a particularly aggressive cancer subtype without specific therapeutic options, our findings suggest that pharmacological inhibition of either AGR2 or its upstream regulator, FOXM1, may be beneficial for PIMA patients. This evidence concerns the gene FOXM1 and cancer.